Last reviewed · How we verify
Angiotensin II Type 1 Receptor Blocker
Angiotensin II Type 1 Receptor Blockers (ARBs) block the angiotensin II receptor on blood vessel walls, preventing vasoconstriction and reducing blood pressure.
Angiotensin II Type 1 Receptor Blockers (ARBs) block the angiotensin II receptor on blood vessel walls, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.
At a glance
| Generic name | Angiotensin II Type 1 Receptor Blocker |
|---|---|
| Also known as | Angiotensin Receptor Blocker, ARB |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Angiotensin II Type 1 Receptor Blocker (ARB) |
| Target | AT1 receptor (Angiotensin II Type 1 Receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ARBs selectively antagonize the AT1 receptor, which is responsible for the vasoconstrictive and aldosterone-releasing effects of angiotensin II. By blocking this receptor, ARBs cause vasodilation, reduce peripheral vascular resistance, and lower blood pressure. They also reduce sodium reabsorption in the kidneys and have cardioprotective effects in heart failure and post-myocardial infarction patients.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
Key clinical trials
- Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients (PHASE2)
- Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy (PHASE4)
- The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI (PHASE3)
- Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (PHASE3)
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (PHASE4)
- Study of Preoperative Management of Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Medications (NA)
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PHASE3)
- Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: